雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察

doi:10.3969/j.issn.1006-7795.2019.03.022

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (3): 443-448.doi: 10.3969/j.issn.1006-7795.2019.03.022

雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察

白向东¹, 郝雅婷¹, 张欣雪², 贺强²

1. 山西省肿瘤医院乳腺三科, 太原 030013;
2. 首都医科大学附属北京朝阳医院普外科, 北京 100020

收稿日期:2018-12-06 出版日期:2019-05-21 发布日期:2019-06-13
通讯作者: 贺强 E-mail:heqiang349@sina.com
基金资助:
国家自然科学基金面上项目（81471590）。

Effects of combined lienal polypeptide injection and postoperative chemotherapy on estrogen receptor-positive and estrogen receptor-negative patients

Bai Xiangdong¹, Hao Yating¹, Zhang Xinxue², He Qiang²

1. The Third Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan 030013, China;
2. Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2018-12-06 Online:2019-05-21 Published:2019-06-13
Supported by:
This study was supported by National Natural Science Foundation of China (81471590).

摘要/Abstract

摘要： 目的探讨雌激素受体（estrogen receptor，ER）阳性（ER+）和雌激素受体阴性（ER-）不同分子亚型乳腺癌术后辅助化学药物治疗（简称化疗）中加用脾多肽的临床免疫疗效。方法在山西省肿瘤医院乳腺外科2014年1月至2017年12月收治的原发乳腺癌术后辅助化疗的患者201例，其中109例ER+乳腺癌患者，92例ER-乳腺癌患者。ER+组乳腺癌患者采用数字表法随机分为实验亚组和对照亚组，对照组采用常规的化疗方案，实验组在对照组的基础上加用脾多肽注射液，比较两亚组治疗前后的免疫功能及不良反应的影响。ER-组也采用同样的处理。结果 ER+实验亚组和对照亚组相比，T细胞总数、CD4⁺、CD8⁺在治疗前后差异有统计学意义（P<0.05），且治疗后T细胞总数、CD4⁺、CD8⁺均增高；可溶性白细胞介素-2受体（soluble interleukin-2 receptor，SiL-2R）和恶性肿瘤特异性生长因子（tumor specific growth factor，TSGF）浓度下降，差异具有统计学意义（P<0.05），重度（Ⅲ、IV度）骨髓抑制比例降低，发生口腔黏膜炎的比例下降，严重恶心呕吐（Ⅲ、IV度）患者比例明显降低，化疗血液毒性和消化道反应明显减轻。ER-实验亚组和对照亚组相比，治疗后总T细胞、CD4⁺、CD8⁺显著增高，差异有统计学意义；Sil-2R显著降低，差异有统计学意义；同时化疗血液毒性和消化道反应明显减轻。结论脾多肽注射液在不同分子亚型乳腺癌术后辅助化疗中均能提高患者免疫功能、减轻化疗不良反应，值得在临床上进一步推广。

关键词: 脾多肽, 雌激素受体, 乳腺癌, 免疫功能

Abstract: Objective In this study, the effects of lienal polypeptide injection (LPI) combined postoperative chemotherapy on patients with breast cancer were explored. Methods Totally 201 cases with primary breast cancer from January 2014 to December 2017 received adjuvant chemotherapy, including 109 cases with estrogen receptor positive (ER+) breast cancer and 92 cases with ER negative (ER-) breast cancer in Shanxi Province Cancer Hospital.Breast cancer patients in the ER+ group were randomly divided into the experimental subgroup and the control subgroup. The control subgroup was treated with conventional chemotherapy, and the experimental group was additionally given LPI. The effects of immune function, toxic and side effects in the two subgroups were compared.The same process was used for ER-groups.Results Compared with the control subgroup, the total number of T cells, CD4⁺ and CD8⁺ in the ER+ experimental subgroup and in the ER-experimental subgroup were significantly different before and after treatment (P<0.05), and the total number of T cells, CD4⁺ and CD8⁺ were increased after treatment. Compared with the control subgroup,the levels of soluble interleukin receptor-2 (SiL-2R) and malignant tumor specific growth factor (TSGF) in ER+ experimental subgroup were significantly different before and after treatment (P<0.05),and Sil-2R and TSGF decreased. Compared with the control subgroup, Sil-2R decreased significantly in the ER-experimental subgroup.The proportion of severe myelosuppression (grade Ⅲ, IV) was decreased, the proportion of oral mucositis was decreased, and the proportion of severe nausea and vomiting (grade Ⅲ, IV) was significantly reduced. The adverse reactions of high grade were greatly relieved in the ER+ experimental subgroup and in the ER-experimental subgroup.Conclusion It has improved that LPI is effective in improving the immune function, which is worth promoting in the clinical practices.

Key words: lienal polypeptide injection (LPI), estrogen receptor, breast cancer, immune function

中图分类号:

白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.

Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Effects of combined lienal polypeptide injection and postoperative chemotherapy on estrogen receptor-positive and estrogen receptor-negative patients[J]. Journal of Capital Medical University, 2019, 40(3): 443-448.

[1]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[2]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[3]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[4]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[7]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[8]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[9]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[10]	张凌燕, 阮祥燕, 蔡桂举, 谷牧青, Alfred O. Mueck. 他莫昔芬治疗转染孕激素受体膜组分1乳腺癌裸鼠模型对乳腺肿瘤组织Ki-67表达的影响[J]. 首都医科大学学报, 2019, 40(4): 533-538.
[11]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[12]	陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.
[13]	李雪, 阮祥燕, 谷牧青, 蔡桂举, 赵越, Alfred O. Meuck. 孕激素受体膜组分1促进雌孕激素诱导的乳腺癌细胞增生的研究——雌二醇与周期序贯及连续联合比较[J]. 首都医科大学学报, 2019, 40(2): 237-243.
[14]	徐泉, 刘玉洁, 潘钰, 郑秀瑗, 刘静民, 孙小花, 邹丽丽, 马丽娜, 严红松. 生物电阻抗测试频率对乳腺癌相关淋巴水肿定量评估的影响[J]. 首都医科大学学报, 2018, 39(5): 747-751.
[15]	张颖, 阮祥燕, 蔡桂举, 苏雅洁, 李娜, Alfred O. Mueck. 不同激素受体作为乳腺癌预后标志物的研究进展[J]. 首都医科大学学报, 2018, 39(4): 479-485.

雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察

Effects of combined lienal polypeptide injection and postoperative chemotherapy on estrogen receptor-positive and estrogen receptor-negative patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价